Literature DB >> 12464801

Haplotype structure of the UDP-glucuronosyltransferase 1A1 promoter in different ethnic groups.

Federico Innocenti1, Carrie Grimsley, Soma Das, Jacqueline Ramírez, Cheng Cheng, Hala Kuttab-Boulos, Mark J Ratain, Anna Di Rienzo.   

Abstract

Genetic variation in UDP-glucuronosyltransferase 1A1 (UGT1A1)expression has several important clinical implications. UGT1A1 basal transcription is affected by a polymorphic (TA)n repeat, and another important regulatory element is the phenobarbital-responsive enhancer module (PBREM) which might contain variants affecting inducible gene expression. We assessed the extent of linkage disequilibrium between the (TA)n polymorphism and variants in the PBREM and UGT1A1 promoter. We also investigated the relationship between PBREM-(TA)n haplotypes and the glucuronidation rate of the UGT1A1 substrate SN-38. DNAs from 83 human livers were genotyped for the (TA)n polymorphism and microsomes from the same livers were phenotyped for SN-38 glucuronidation. The (TA)n polymorphism was genotyped in 24 additional African-Americans included in the Human Variation Panel (Coriell Institute). A 606-bp region spanning the PBREM was sequenced in 81 liver and a subset of 22 Human Variation Panel DNAs and six variants were found. The -3279G T and -3156G A variants are common (0.39 and 0.30, respectively). -3279G T is more common in Caucasians than African-Americans (P = 0.001). In Caucasians, linkage disequilibrium was highly significant between sites -3279, -3156, and the (TA)n polymorphism (P < 0.0001). In contrast, in African-Americans, only marginal levels of significance were observed between (TA)n and -3279 (P = 0.02) and between -3279 and -3156 (P = 0.04). Ten promoter haplotypes were identified. Haplotype I is the most common (0.39), from which haplotype II (0.15) differs at position -3279. SN-38G formation rates were correlated with (TA)n genotypes. This study showed that (i) common promoter variants are in linkage disequilibrium and (ii) the haplotype structure of promoter is probably different between Caucasians and African-Americans. Copyright 2002 Lippincott Williams & Wilkins

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12464801     DOI: 10.1097/00008571-200212000-00006

Source DB:  PubMed          Journal:  Pharmacogenetics        ISSN: 0960-314X


  36 in total

1.  Mapping of the UGT1A locus identifies an uncommon coding variant that affects mRNA expression and protects from bladder cancer.

Authors:  Wei Tang; Yi-Ping Fu; Jonine D Figueroa; Núria Malats; Montserrat Garcia-Closas; Nilanjan Chatterjee; Manolis Kogevinas; Dalsu Baris; Michael Thun; Jennifer L Hall; Immaculata De Vivo; Demetrius Albanes; Patricia Porter-Gill; Mark P Purdue; Laurie Burdett; Luyang Liu; Amy Hutchinson; Timothy Myers; Adonina Tardón; Consol Serra; Alfredo Carrato; Reina Garcia-Closas; Josep Lloreta; Alison Johnson; Molly Schwenn; Margaret R Karagas; Alan Schned; Amanda Black; Eric J Jacobs; W Ryan Diver; Susan M Gapstur; Jarmo Virtamo; David J Hunter; Joseph F Fraumeni; Stephen J Chanock; Debra T Silverman; Nathaniel Rothman; Ludmila Prokunina-Olsson
Journal:  Hum Mol Genet       Date:  2012-01-06       Impact factor: 6.150

Review 2.  Uridine 5'-diphospho-glucuronosyltransferase genetic polymorphisms and response to cancer chemotherapy.

Authors:  Jacqueline Ramírez; Mark J Ratain; Federico Innocenti
Journal:  Future Oncol       Date:  2010-04       Impact factor: 3.404

Review 3.  The role of pharmacogenetics in cancer therapeutics.

Authors:  Wei Peng Yong; Federico Innocenti; Mark J Ratain
Journal:  Br J Clin Pharmacol       Date:  2006-07       Impact factor: 4.335

Review 4.  Gender specific tumour pharmacology--from kinetics to genetics.

Authors:  Robert M Mader
Journal:  Wien Med Wochenschr       Date:  2006-10

5.  UGT1A1 and UGT1A9 functional variants, meat intake, and colon cancer, among Caucasians and African-Americans.

Authors:  Hugo Girard; Lesley M Butler; Lyne Villeneuve; Robert C Millikan; Rashmi Sinha; Robert S Sandler; Chantal Guillemette
Journal:  Mutat Res       Date:  2008-07-16       Impact factor: 2.433

6.  Dose-finding and pharmacokinetic study to optimize the dosing of irinotecan according to the UGT1A1 genotype of patients with cancer.

Authors:  Federico Innocenti; Richard L Schilsky; Jacqueline Ramírez; Linda Janisch; Samir Undevia; Larry K House; Soma Das; Kehua Wu; Michelle Turcich; Robert Marsh; Theodore Karrison; Michael L Maitland; Ravi Salgia; Mark J Ratain
Journal:  J Clin Oncol       Date:  2014-06-23       Impact factor: 44.544

7.  Association of pharmacogenetic markers with premature discontinuation of first-line anti-HIV therapy: an observational cohort study.

Authors:  Rubin Lubomirov; Sara Colombo; Julia di Iulio; Bruno Ledergerber; Raquel Martinez; Matthias Cavassini; Bernard Hirschel; Enos Bernasconi; Luigia Elzi; Pietro Vernazza; Hansjakob Furrer; Huldrych F Günthard; Amalio Telenti
Journal:  J Infect Dis       Date:  2010-12-09       Impact factor: 5.226

Review 8.  Pharmacogenomics in colorectal cancer: the first step for individualized-therapy.

Authors:  Eva Bandrés; Ruth Zárate; Natalia Ramirez; Ana Abajo; Nerea Bitarte; Jesus Garíia-Foncillas
Journal:  World J Gastroenterol       Date:  2007-11-28       Impact factor: 5.742

9.  Do Alpha Thalassemia, Fetal Hemoglobin, and the UGT1A1 Polymorphism have an Influence on Serum Bilirubin Levels and Cholelithiasis in Patients with Sickle Cell Disease?

Authors:  Laura Alencastro de Azevedo; Joyce Bonazzoni; Sandrine Comparsi Wagner; Mariela Granero Farias; Christina M Bittar; Liane Daudt; Simone Martins de Castro
Journal:  Mol Diagn Ther       Date:  2017-08       Impact factor: 4.074

10.  Combined effect of regulatory polymorphisms on transcription of UGT1A1 as a cause of Gilbert syndrome.

Authors:  Katsuyuki Matsui; Yoshihiro Maruo; Hiroshi Sato; Yoshihiro Takeuchi
Journal:  BMC Gastroenterol       Date:  2010-06-08       Impact factor: 3.067

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.